MARLBOROUGH, Mass., April 20, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present new data from the Company's consumer product development program, based on its proprietary self-delivering RNAi (sd-rxRNA®) technology, at the Society for Investigative Dermatology (SID) 76th Annual Meeting. The SID mission is to advance and promote the sciences relevant to skin health and disease through education, advocacy and scholarly exchange of scientific information. This annual meeting is being held April 26-29, 2017 at the Oregon Convention Center in Portland Oregon.
- Topical Application of Self-delivering RNAi (sd-rxRNA) Compounds for Reduction of Hyperpigmentation
RXI-231: sd-rxRNA Targeting Tyrosinase (TYR)
This poster will show that reduction of tyrosinase mRNA levels by sd-rxRNA in cultured cells leads to a decrease in visible pigmentation and melanin content, in line with the expected mechanism of action of an RNAi compound. In addition, as demonstrated ex vivo in pig skin, our proprietary formulation allows for the non-invasive penetration of sd-rxRNA compounds to the epidermal dermal junction where TYR-producing melanocytes reside. Consumer testing will initiate in May 2017.
Date and Time: April 29, 2017 10:15 AM PDT
Presented by: Melissa Maxwell
Session 3: Pigmentation and Melanoma
Poster #: 810, Exhibit Hall A
- Prevention of UVR Induced MMP1 Upregulation with an MMP1 Targeting Self-delivering RNAi (sd-rxRNA) Compound May Reduce the Effects of Skin Photo-aging
RXI-185: sd-rxRNA Targeting Collagenase (MMP1)
Results from a collaboration with DSM, one of the industry's leading suppliers of ingredients and innovative solutions for beauty care products, will be presented. This poster will show that RXI-185 is capable of reducing MMP1 mRNA levels and enzyme activity in cultured human dermal fibroblasts and in an in vitro human skin model after UVR-induced MMP1 upregulation. In addition, Fl-RXI-185 is capable of reducing MMP1 mRNA levels following topical administration in an ex vivo human skin model.
Date and Time: April 29, 2017 10:15 AM PDT
Presented by: Katherine Holton
Session 3: Photobiology
Poster #: 756, Exhibit Hall A
Additional information on DSM may be found by visiting their website, www.dsm.com.
RXi's consumer health compounds are intended to affect the appearance of the skin. As a consumer health product, no preventative or therapeutic claims can be made. However, these compounds may be developed more rapidly than therapeutics and, therefore, the path to the market may be shorter and less expensive.
Both posters will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following each presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA) Technology Platform
RXi's proprietary sd-rxRNA technology has many advantages over its competitors in the RNAi space. Scientists at RXi have designed chemically-modified RNAi compounds with improved drug-like properties that are potent, stable and specific. These proprietary compounds have built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications. The enhanced properties of sd-rxRNA include: efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity. All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing. sd‑rxRNA compounds have the ability to selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. Additional information may be found on the Company's website, www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-an-update-on-its-consumer-product-development-programs-at-the-society-for-investigative-dermatology-76th-annual-meeting-300442522.html
SOURCE RXi Pharmaceuticals Corporation